- AdventHealth Research Institute
A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.
While obesity has long been linked to these cancers, the research suggests Type 2 diabetes itself may be an independent driver of cancer risk. The findings, presented at the 2025 European Congress on Obesity, analyzed data from over 23,000 people in the U.K. Biobank with new-onset Type 2 diabetes and compared them to more than 71,000 non-diabetic individuals of similar age, sex, and weight.
Over five years, cancer risk was clearly higher in the diabetes group:
- Liver cancer risk was nearly 4 times higher in men and 5 times higher in women.
- Pancreatic cancer risk rose 74% in men, nearly doubled in women.
- Colorectal cancer risk increased by more than 25% in both groups.
Lead author Owen Tipping from the University of Manchester said the link may stem from factors like inflammation, insulin resistance, or gut microbiome changes—beyond just excess weight.
Experts say more research is needed but agree the findings highlight the importance of early detection, healthy lifestyle changes, and ongoing monitoring. “This isn’t a reason to panic,” said oncologist Dr. Jack Jacoub. “It’s a reason to take action—through diet, exercise, and good blood sugar control.”
The takeaway? Type 2 diabetes may do more than disrupt blood sugar—it could quietly raise your cancer risk too.
Recent News
Bringing Cancer Research Into the Home: Dr. Justin Brown's Approach to Trial Design
Justin Brown, PhD, Associate Investigator at AdventHealth, has dedicated his career to studying how exercise can improve outcomes for cancer patients after losing his father to colon cancer as a...
Exercise as “Powerful Medicine”: Spotlight on AdventHealth Research
Recently, Dr. Bret Goodpaster, scientific director of the AdventHealth Translational Research Institute (TRI), appeared on FOX 35 News to discuss groundbreaking research exploring how exercise impacts...
New Study Points to Promising Way to Protect Kidneys in Type 1 Diabetes
Richard E. Pratley, M.D., senior investigator and diabetes program lead at the AdventHealth Translational Research Institute (TRI), served as one of the lead researchers on the international FINE-ONE...
Understanding Hypoglycemia and the CLEAR Study
The CLEAR Study is a groundbreaking, international research effort funded by the NIH that aims to help people with Type 1 diabetes (T1D) who can no longer sense when their blood sugar is dangerously...
Recognizing the Unrecognized: Advancing Research in Childhood Sjögren’s Disease
Sjögren’s disease has been recognized in adults for almost a century, first described by Swedish ophthalmologist Henrik Sjögren in the early 20th century. One of the biggest challenges in recognizing...
Did you know? Women, Hormones, and Heart Risk
Heart disease is often thought of as a “man’s disease,” but it remains the leading cause of death for women in the United States. We asked Katie Love, MD, MSc, an investigator at the AdventHealth...
Weight-Loss Drugs, Hormones, and Midlife: What Women Need to Know
Understanding the connection between GLP-1 medications and hormone therapy
Women, Brain Health, and the Alzheimer’s Puzzle
Why scientists are taking a closer look at why women face higher Alzheimer’s risk
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.
AdventHealth Tampa Enrolls First Patient in the Tectonic CAD IVL Trial
On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.